UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 11, 2016

 

IMMUDYNE, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   333-184487   76-0238453
(State or other Jurisdiction of
Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

50 Spring Meadow Rd.

Mount Kisco, NY

  10549
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (914) 244-1777

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item 2.02.  Results of Operations and Financial Condition.

 

On October 11, 2016, Immudyne, Inc. (the “Company”) issued a press release announcing the Company’s preliminary financial results for the period ended September 30, 2016, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information in this Item 2.02 of this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

Item 7.01.  Regulation FD Disclosure

 

On October 12, 2016, the Company released a new corporate presentation. Attached hereto as Exhibit 99.2 and made part of this report, is a copy of this presentation.

 

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01.  Financial Statements and Exhibits

 

(d) Exhibits
   
99.1 Press Release of Immudyne, Inc., dated October 11, 2016, with respect to the Company’s preliminary financial results for period ended September 30, 2016 (furnished only).
   
99.2 Immudyne, Inc. corporate presentation Q4 2016 (furnished only)

 

 2 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUDYNE INC.
  (Registrant)
   
Date: October 12, 2016 By: /s/ Mark McLaughlin
  Name: Mark McLaughlin
  Title: Chief Executive Officer

 

 

3